NASDAQ:MOR MorphoSys (MOR) Stock Price, News & Analysis $18.96 0.00 (0.00%) As of 06/22/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About MorphoSys Stock (NASDAQ:MOR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MorphoSys alerts:Sign Up Key Stats Today's Range$18.96▼$18.9650-Day Range$18.96▼$18.9652-Week Range$4.18▼$19.50VolumeN/AAverage Volume1.02 million shsMarket Capitalization$2.86 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MorphoSys AG is a clinical‐stage biopharmaceutical company specializing in the discovery and development of therapeutic antibodies for the treatment of cancer, autoimmune and inflammatory diseases. The company employs a proprietary human antibody library technology platform (HuCAL®) to generate fully human monoclonal antibodies and bispecific antibody formats. MorphoSys focuses on advancing its own pipeline programs while forging strategic partnerships and licensing agreements with major pharmaceutical companies to co‐develop and commercialize novel antibody therapies. The company’s lead programs include tafasitamab (Monjuvi®), an anti‐CD19 immunotherapy approved in the United States for certain types of relapsed or refractory diffuse large B‐cell lymphoma, and pelabresib, an investigational BET inhibitor being evaluated in collaboration with GlaxoSmithKline for the treatment of myelofibrosis. In addition to its oncology focus, MorphoSys is advancing antibody candidates in areas such as solid tumors and autoimmune conditions. The company’s R&D operations are supported by research facilities in Planegg‐Martinsried, Germany, complemented by commercial and clinical development teams based in Cambridge and Boston, Massachusetts. Founded in 1992 and headquartered near Munich, MorphoSys has built a global presence through collaborations and licensing deals with industry partners, including Incyte, Novartis and Janssen Biotech. The company’s shares trade on the NASDAQ under the symbol MOR and on the Frankfurt Stock Exchange. Under the leadership of President and CEO Jean-Paul Kress, MorphoSys continues to leverage its antibody engineering expertise to expand its pipeline, drive clinical programs forward and explore new therapeutic areas.AI Generated. May Contain Errors. Read More Receive MOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MOR Stock News HeadlinesComparing BetterLife Pharma (OTCMKTS:PVOTF) & MorphoSys (NASDAQ:MOR)June 20, 2026 | americanbankingnews.comMorphosys AG : MORMay 31, 2026 | 247wallst.comEvery time Musk needs a company, he buys itMusk needed batteries - he built the Gigafactory. Needed solar - acquired SolarCity. Needed data - bought Twitter. The pattern is consistent: when a supplier becomes mission-critical, he acquires it. Now, with $75 billion raised in the largest IPO in history, one small power infrastructure company is the critical piece his $2 trillion empire can't run without. Dylan Jovine has the name and ticker. | Behind the Markets (Ad)Novartis notches another win for drug acquired in MorphoSys dealDecember 9, 2025 | finance.yahoo.comNovartis' Avidity Deal: Growth Accretive, Multiple Gated By ExecutionOctober 27, 2025 | seekingalpha.comMyelofibrosis Market Overview: Epidemiology, Therapies, and Key Players include AbbVie, Morphosys, Geron, Bristol Myers Squibb, Kartos Therapeutics, Karyopharm Therapeutics, NS ...October 7, 2025 | theglobeandmail.comMaxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development OfficerJune 17, 2025 | finance.yahoo.comEssential Thrombocythemia Market Set for Significant Growth Across 7MM | DelveInsightMarch 21, 2025 | theglobeandmail.comSee More Headlines MOR Stock Analysis - Frequently Asked Questions How have MOR shares performed this year? MorphoSys' stock was trading at $18.96 at the beginning of the year. Since then, MOR shares have increased by 0.0% and is now trading at $18.96. When did MorphoSys IPO? MorphoSys (MOR) raised $200 million in an IPO on Thursday, April 19th 2018. The company issued 8,300,000 shares at a price of $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers. How do I buy shares of MorphoSys? Shares of MOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MorphoSys own? Based on aggregate information from My MarketBeat watchlists, some other companies that MorphoSys investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), e.l.f. Beauty (ELF), EMCOR Group (EME), Disc Medicine (IRON) and Builders FirstSource (BLDR). Company Calendar Today6/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MOR CIK1340243 Webwww.morphosys.com Phone(498) 989-9270Fax49-89-8992-7222Employees730Year Founded1992Profitability EPS (Trailing Twelve Months)($3.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$205.35 million Net Margins-226.79% Pretax Margin-225.77% Return on Equity-694.31% Return on Assets-22.55% Debt Debt-to-Equity Ratio4.98 Current Ratio1.38 Quick Ratio1.38 Sales & Book Value Annual Sales$238.28 million Price / Sales11.99 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book54.17Miscellaneous Outstanding Shares150,621,000Free Float150,546,000Market Cap$2.86 billion OptionableNot Optionable Beta1.20 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:MOR) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...Stansberry Research | SponsoredQuick favor to ask youBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTop Banks Warn: A Strange Day is Coming to AmericaGoldman Sachs and Morgan Stanley are warning clients about a developing crisis that could suppress portfolio g...TradeSmith | SponsoredA drilling crew just broke a record nobody expectedA drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...Behind the Markets | SponsoredElon Musk, Larry Fink & Brian Armstrong are ALL Piling into ThisElon Musk, BlackRock CEO Larry Fink, and Coinbase CEO Brian Armstrong are all quietly investing in the same te...Brownstone Research | SponsoredKarp just filed Form 144On May 12, 2026, Palantir CEO Alex Karp filed to sell 585,000 shares - roughly $95.93 million. Combined with f...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
